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Glutamine synthetase (GS) is an essential enzyme in nitrogen metabolism and catalyses the
ATP-dependent ligation of glutamate and toxic ammonia to glutamine. So far, three GS mu-
tants with clinically relevant pathologies are known. These mutations lead to hyperammonemia
and a global glutamine deficiency. Recently, we investigated the molecular mechanisms un-
derlying these mutations. However, an adequate treatment for a patient carrying the R324S
mutation, now eleven years old, remains elusive. Here, we investigate by means of unbiased
molecular dynamics simulations if and how the compatible solute betaine, successfully used for
the treatment of liver diseases, can restore GS catalytic activity in the case of R324S GS. Upon
free ligand diffusion, betaine enters the R324S GS binding site and forms hydrogen bonds with
S324 and weak electrostatic interactions with ATP. Thus, betaine could act as a non-covalently
bound ATP binding-enhancer in the case of R324S GS.
1 Introduction
The human glutamine synthetase (GS, EC 6.3.1.2) is a homodecamer in which ten sub-
units form two pentameric rings that stack onto each other (Fig. 1A)1. GS catalyses the
conversion of glutamate and ammonia to glutamine under the use of adenosine triphos-
phate (ATP)2. Thus, GS contributes to glutamate and ammonia detoxification3, 4, as well as
to glutamine formation, which makes GS essential for the human nitrogen metabolism5, 6.
Two GS mutations, R324C and R341C (sequence numbering of human GS1), were linked
to a reduced GS activity and led to severe brain malformations and multiorgan failure,
which results in neonatal death9, 10. Another GS mutation, R324S, was identified in a boy,
who is neurologically compromised due to the lack of ammonia detoxification and glu-
tamine synthesis11. The boy had been initially treated with glutamine supplementation12.
However, the treatment was stopped after the patient showed an increased irritability. Thus,
no adequate medication is currently available to treat inborn GS deficiency caused by the
R324S mutation. Recently, we showed that ATP binding is hampered in the R324S mutant
because a salt-bridge interaction between R324 and ATP is lost in the case of the R324S
mutant13. Additionally, the R324S mutant results in a gap between the S324 sidechain and
ATP13.
In search of a treatment of this rare disease, we aim at identifying small molecules that
can act as ATP binding-enhancing molecules, thereby restoring GS activity in the R324S
mutant. Here, we focus on trimethyl glycine (betaine, Fig. 1B) as one such molecule.
From a structural point of view, betaine could bridge the gap between S324 and ATP by
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Figure 1. Human glutamine synthetase, betaine, and starting structures for unbiased MD simulations. A: Top
view (left panel) and side view (right panel) of the human glutamine synthetase (GS) (PDB entry: 2QC81). Each
subunit is coloured differently and shown in surface representation. Subunits A and B were used for a reduced
dimeric model. The black box depicts the catalytic site. B: Schematic (left panel) and optimised 3D structure
(right panel; ball-and-stick model without hydrogens) of the betaine molecule as used for MD simulations. C:
Starting structure (“GSAPO model”) (black cartoon ) of the R324S GS with∼150 mM of betaine (green spheres)
in a truncated octahedron of TIP3P15 waters (blue surface representation). D: Close up view of the GS binding
site. The upper panel shows wild type R324 (green) with labelled reference atoms and ATP (blue). Salt-bridge
interactions are depicted as black dotted lines. The lower panel shows another starting structure (“GSATP model”)
of the R324S GS mutant (magenta) with bound ATP (blue) and betaine (green) with labelled reference atoms.
forming hydrogen bonds and electrostatic interactions with S324 and ATP, respectively.
From a clinical point of view, betaine is a safe, well tolerated, and inexpensive drug, and
dietary betaine supplementation improved serum levels of liver enzymes in the context of
fatty liver diseases14. We assessed if the GS binding site is accessible for betaine by means
of unbiased molecular dynamics (MD) simulations of betaine diffusion in the presence of
R324S GS. Moreover, we determined, if betaine simultaneously interacts with S324 and
ATP and stabilises ATP binding.
2 Methods
To investigate if the R324S GS binding site is accessible for betaine, we performed un-
biased MD simulations of R324S GS in the GSAPO state in the presence of ∼150 mM of
betaine (the preparation of the GSAPO state is described in Ref. 13). We randomly placed 92
betaine molecules around the R324S GS using PACKMOL16. Furthermore, to test whether
a single betaine molecule can stably span the interaction between S324 and the phosphate
groups of the GS substrate ATP, we generated an additional model with betaine and ATP
bound to R324S GS (further referred to as GSATP state; for preparation of the GSATP state
see Ref. 13). The coordinates of R324 atoms Cδ, N, and Cζ were assigned to the betaine
atoms C1, C2, and N1 such that the betaine’s carboxyl function is oriented towards S324
and the quaternary ammonium function towards ATP (Fig. 1D). After neutralising both the
GSAPO and GSATP systems by adding sodium ions, the systems were placed in a truncated
octahedron of TIP3P water15. Following thermalisation, both systems were subjected to
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three independent MD simulations of 100 ns length using Amber1417 (simulation parame-
ters are described in Ref. 13). Results are expressed as means. Mean standard error (MSE)
is < 0.02 A˚, unless specified differently. A one-sample Student’s t-test was performed
using the R software19.
3 Results and Discussion
To test if betaine can enhance ATP binding to the R324S mutant of GS and restore GS
activity that way, we performed three unbiased MD simulations of 100 ns length of the
GSAPO state of the R324S mutant in the presence of ∼150 mM of betaine (Fig. 1C). Ini-
tially, we assessed whether the R324S GSAPO model is stable in the presence of betaine.
The mean backbone root mean square deviation (RMSD) of R324S GS is < 2.9 A˚, but
some conformations showed RMSD values close to 5.0 A˚ (Fig. 2A). Visual inspection of
the trajectories revealed that those regions of the dimer are highly mobile where adjacent
subunits would be located in the decamer13. Excluding these regions from the RMSD
calculations (resulting in what is termed GScore below) yielded backbone RMSD values
that are largely constant and < 3.0 A˚ with mean RMSD values for the GScore < 2.0 A˚
(Fig. 2B). As the catalytic site is located at the interface between the two subunits of the
dimeric model (Fig. 1A) and, hence, in the centre of GScore, we conclude that the dimeric
GSAPO model is appropriate for investigating putative effects exerted by betaine at the cat-
alytic site. Considering the first 20 ns as an extended equilibration phase, further analyses
focused on the 20 - 100 ns interval.
Next, we analysed if betaine can enter the catalytic site of R324S GS because this will
be a prerequisite for any direct betaine effect on ATP binding. For this, we computed
density maps from the MD trajectories showing the frequency of interactions of betaine
on the surface of R324S GS. Regions of high betaine density across all three trajectories
are labelled a to f in Fig. 2C. Additional regions are visible in one or two of the MD
trajectories only, suggesting that sampling of the unbound state of betaine is not converged
after 100 ns of MD simulations. One region was identified where betaine is frequently
present within the ATP binding site (Fig. 2D). Monitoring the minimal distance between
the two carboxylate oxygens of betaine and the sidechain oxygen of S324 reveals for one
MD trajectory that the betaine molecule enters the binding site after ∼30 ns and then
remains there for the remainder of the trajectory, reaching a minimal distance to S324 of
6.2 A˚ (Fig. 2D). As an explanation, betaine immediately binds to one of the Mg2+ ions
within the binding site that would interact with ATP; the Mg2+ ions are important for GS
activity20. In agreement with the slow exchange kinetics of first shell ligands of Mg2+,21
no unbinding of betaine from Mg2+ is observed during ∼70 ns of MD simulations. We
hypothesise that the bound betaine will be displaced from the Mg2+ by subsequent binding
of ATP; due to the low likelihood of observing two simultaneous binding events within
the accessible time scale of MD simulations, we are at present unable to validate this
hypothesis, however. Additional regions of high betaine density close to the glutamate
binding site were identified in all three trajectories (Fig. 2E). However, no betaine molecule
finally entered the glutamate binding site. This is likely because glutamate binding to GS
is highly regulated by an ATP-dependent opening and closing mechanism of the glutamate
binding site1. As we disregarded ATP during MD simulations, the glutamate binding site
is shielded by several loop regions (Fig. 2E), preventing betaine from entering it.
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Figure 2. Unbiased MD simulations of betaine diffusion in the presence of R324S GS. A: Backbone RMSD of
R324S GS in the GSAPO state for three trajectories. Mean values are provided in the legend. B: Backbone RMSD
for GScore residues of R324S GS in the GSAPO state for three trajectories. Mean values are provided in the legend.
C: Overlay of density maps (depicted as isocontour mesh; contour level is 80 sigma) showing the frequency of
betaine interactions on the surface of R324S GSAPO (white cartoon representation) of trajectory 1 (orange), 2
(green), and 3 (magenta). Labels a to f depict regions of high betaine density coherently found in all trajectories.
D: The top panel shows a close up view of the ATP binding site with regions of high betaine density. The lower
panel shows the minimal distance between the two carboxylate oxygens of the respective betaine molecule and
the sidechain oxygen of S324 for the 20 - 100 ns interval of trajectory 2. E: Close up view of regions of high
betaine density close to the glutamate binding site. For panels D and E, ATP (blue ball-stick model) and glutamate
(yellow ball-stick model) were added only to visualise their location; both molecules were not present during the
MD simulations. Residue S324 is depicted in magenta.
Next, to probe if betaine stably binds between S324 and ATP, thereby bridging the gap
between the amino acid’s side chain and ATP, we performed three additional MD simula-
tions of 100 ns length in which a single betaine molecule was initially placed in the gap
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Figure 3. Structural analyses of betaine bound to the R324S glutamine synthetase binding site. A: Close up
view of betaine (green) in the S324 GS binding site with residue S324 (purple) and ATP (blue) as blue ball-stick
models. The geometric centre (GC) of the betaines trimethyl amine group is depicted as cyan sphere. Distances
1 - 4 (see text for definitions) are shown as dotted magenta lines. B: Distances 1 - 4 over trajectories 1, 2, and
3 (purple, orange, and red lines) with respective mean values in the legend. For distance 1, only the smallest
distance to one of the oxygens of the carboxylate group of betaine, and for distance 2 - 4, only the smallest
distance to one of the oxygens of the α, β, and γ phosphate groups in ATP are considered, respectively. C: Mean
RMSF of ATP over three trajectories (mean standard error depicted as error bars). The white bar shows RMSF
values in the absences (-) of betaine (MD simulations were previously described in Ref. 13), the blue bar in the
presence (+) of betaine.
(Fig. 1D). To analyse hydrogen bond formation with S324 and formation of an electro-
static interaction between the positively charged trimethylamine function in betaine and
the negatively charged phosphate groups of ATP, we measured four distances (Fig. 3A).
Distance 1, measured as minimal distance between the two carboxylate oxygens of the be-
taine molecule and the sidechain oxygen of S324, is rather constant in trajectories 2 and 3
with mean distances of 2.73 A˚ and 2.74 A˚ (Fig. 3B). In these trajectories, a hydrogen bond
(using a distance of 3.2 A˚ between the two donor and acceptor atoms and an angle (donor
atom, H, acceptor atom) of 120◦ as cutoff criteria18) is present between both functional
groups in at least 90% of all conformations. The smallest distances between the geometric
centre of the quaternary ammonium group in betaine to one of the oxygens of the α, β, and
γ phosphate groups in ATP, respectively, show the overall smallest mean values across all
three trajectories in the case of the β phosphate group (values between 4.10 A˚ and 4.89 A˚).
In the case of trajectory 3, a small mean value of 4.01 A˚ is found with respect to the α
phosphate group, too. Considering that the radial distribution function between nitrogen
atoms of the choline cation and oxygen atoms of alanine anions revealed favourable inter-
actions between both groups in a distance range from 4.00 A˚ to 6.0 A˚22, we suggest that
such interactions also exist between betaine and at least the β phosphate group of ATP. To-
gether with the hydrogen bond analysis above, our results suggest that betaine can bridge
the gap between S324 and ATP and, thus, enhance ATP binding.
To investigate whether betaine has a stabilising effect on ATP binding to R324S GS,
we calculated the root mean square fluctuation (RMSF) of ATP in the presence of betaine
after superimposition of backbone atoms of residues within 5 A˚ of ATP in the starting
structure (Fig. 3C, blue bar). We compared values to those extracted from MD simula-
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tions of R324S GS in the GSATP state without betaine, which were described in Ref. 13
(Fig. 3C, white bar). The RMSF value decreases from 0.61 A˚ (± 0.03 A˚) without betaine
to 0.52 A˚ (± 0.04 A˚) in the presence of betaine (Fig. 3C); the difference is weakly signif-
icant (p = 0.11). As the RMSF is a measure of atomic mobility, this indicates that betaine
weakly stabilises ATP binding in the R324S GS binding site, in agreement with the above
geometric analysis of intermolecular interactions.
4 Conclusion and Outlook
The clinically relevant R324S mutation is suggested to reduce catalytic activity of GS12,
which leads to hyperammonemia and a global glutamine deficiency11. Previously, we
found that ATP binding is hampered in the R324S mutant13. Here, we investigated by
MD simulations of in total 600 ns length if betaine can act as an ATP binding-enhancing
molecule. Our results show that betaine can enter the ATP binding site of R324S GSAPO
state and come close to S324. In the GSATP state, betaine simultaneously forms hydro-
gen bonds with S324 and electrostatic interactions with at least the β phosphate group of
ATP. In agreement, betaine binding reduces the mobility of ATP in R324S GS. In all, this
indicates that betaine weakly stabilises ATP binding in the R324S GS binding site.
From our results, several suggestions arise for how to strengthen an ATP binding-
enhancing effect. First, the interactions with the phosphate group may be strengthened
if, instead of the bulky trimethylammonium group of betaine, a positively charged group
such as an amidino or guanidine moiety is chosen that can form salt bridge interactions
with the phosphate oxygens in addition. Glycocyamine (2-guanidino acetate), a metabolite
of glycine, or creatine (2-[amidino(methyl)amino]acetate), a methyl derivative of glyco-
cyamine, which are both used as dietary supplements to treat creatine deficiency23, 24, con-
tain such guanidine groups. Second, the negatively charged carboxylate group of betaine,
which results in disfavourable electrostatic interactions with the phosphate groups, may be
replaced by a neutral hydroxymethyl group, resulting in the positively charged molecule
choline. Choline is used as a dietary supplement25 and in the treatment of liver diseases26.
We intend to investigate these alternatives further by MD simulations and experimental
validation in order to aid in the identification or development of ATP binding-enhancing
molecules by which the R324S GS mutant can be repaired extrinsically27.
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